Inovio Partners with AIDS Malignancy Consortium to Advance

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
51
Inovio Partners with AIDS Malignancy Consortium to Advance Inovio’s HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients

PLYMOUTH MEETING, Pa., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) today announced that it has entered into a partnership with the AIDS Malignancy Consortium (AMC) to evaluate VGX-3100, Inovio’s immunotherapy for treating HPV-associated precancerous conditions in HIV-positive adult men and women. AMC will fund a Phase 2 clinical trial to evaluate the efficacy of VGX-3100 in adult men and women with human papillomavirus (HPV)-related high-grade anal dysplasia or squamous intraepithelial lesions (ASIL) and HIV. Recruitment is already ongoing for patients who are HIV-positive with histologically confirmed anal high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 and/or HPV-18. The multi-site Phase 2 study is planning to enroll approximately 75 patients who will receive four doses of VGX-3100. Financial details of the agreement were not disclosed.

Joel M. Palefsky, MD, Professor of Medicine, Division of Infectious Diseases, UCSF, and founder and chair of the HPV Working Group of the NCI AIDS Malignancy Consortium, said, “The incidence of anal cancer among HIV-positive men and women is unacceptably high. Better methods to treat the anal cancer precursor, known as anal high-grade squamous intraepithelial lesions (HSIL), are needed in an effort to prevent progression from HSIL to cancer. Given the encouraging results with VGX-3100 in treatment of cervical HSIL, the AMC looks forward to testing the immunotherapy for treatment of anal HSIL in this population.”

Dr. J. Joseph Kim, Inovio's President and CEO, said, “Expanding VGX-3100 to treat anal dysplasia represents a significant increase in commercial potential for our lead product. We thank the AMC for partnering with us to test the efficacy of VGX-3100 in a patient community where there is a great unmet need for a successful therapy. For these patients and others, Inovio is moving forward to become the ‘go-to’ immunotherapeutic solution provider for all major diseases caused by HPV, including cervical, vulvar and anal precancers.”

This open-label, multi-center Phase 2 study is designed to evaluate the safety and efficacy of VGX-3100 administered by intramuscular (IM) injection with CELLECTRA® delivery system in adult men and women who are HIV-positive with anal HSIL associated with HPV-16 and/or HPV-18. For additional information about the study, please visit www.clinicaltrials.gov (search identifier NCT03603808).

Separately, Inovio has already initiated a multi-center Phase 2 study designed to evaluate the safety and efficacy of VGX-3100 in 24 HIV-negative patients with anal HSIL associated with HPV-16 and/or HPV-18. The first patient was dosed in July.

Anal HSIL can lead to HPV-associated squamous cell carcinoma of the anus (SCCA). Anal cancer is uncommon in the general population, but its incidence is considerably increasing and is higher among HIV-positive men and women than in HIV-negative persons. The risk of SCCA among HIV-positive men has continued to increase even after the introduction of highly active antiretroviral therapy. Currently, rates of SCCA in HIV-positive men are higher than cervical cancer reported anywhere in the world. This trend is likely to continue with the aging of the HIV-positive population.

Anal cancer is estimated to have nearly 8,600 new cases diagnosed and cause more than 1,100 deaths in the United States in 2018. Currently, the only treatments for anal dysplasia consist of surgical excision, electro-cautery or laser therapy, but more than 50% of those treated with these current treatments experience recurrence of the disease. The HIV population has a significant burden of existing disease which cannot be addressed by current prophylactic approaches.

About the AIDS Malignancy Consortium

The AIDS Malignancy Consortium (AMC) is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers. The AMC is composed of 36 Clinical Trials Sites worldwide, five Working Groups, an Administrative Office, a Statistical Office, and an Operations and Data Management Office. Collectively, these components develop and oversee the scientific agenda, manage the groups’ portfolio of clinical trials and other scientific-based studies, and help to develop new protocols. The AMC mission is to investigate new treatment and prevention interventions for malignancies in people living with HIV and to study the pathobiology of these tumors in the context of clinical trials.

About VGX-3100

VGX-3100 is a DNA-based immunotherapy under Phase 3 investigation for the treatment of HPV-16 and HPV-18 infection and precancerous lesions of the cervix. Inovio has also initiated open-label Phase 2 clinical trials evaluating its efficacy for treating HPV-related vulvar and anal precancers. VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions. VGX-3100 works by stimulating a specific immune response to HPV-16 and HPV-18, which targets the infection and causes destruction of precancerous cells. In a randomized, double-blind, placebo-controlled Phase 2b study in 167 adult women with histologically documented HPV 16/18 cervical HSIL (CIN2/3), treatment with VGX-3100 resulted in a statistically significantly greater decrease in cervical HSIL and clearance of HPV infection vs. placebo. The most common side effect was injection site pain, and no serious adverse events were reported. VGX-3100 utilizes the patient’s own immune system to clear HPV-16 and HPV-18 infection and precancerous lesions without the increased risks associated with surgery, such as loss of reproductive health and negative psychosocial impacts.

About Inovio’s DNA Immunotherapy Technology Platform

Inovio is advancing the medical potential of a unique class of immunotherapy technology. Its DNA-based platform, which is the foundation for all of Inovio’s products, including VGX-3100, is unique in its ability to leverage the body’s naturally existing mechanisms to generate robust, highly targeted immune responses to prevent and treat disease – and to do so in the body without harmful side effects. Its SynCon® immunotherapy design and CELLECTRA® delivery transform novel genetic blueprints into functional antibody and killer T cell responses. Inovio was the first to report the activation – in the body – of significant, antigen-specific functional T cells correlated to statistically significant efficacy in a placebo-controlled, randomized, double-blind Phase 2b clinical trial (HPV-related precancer), with a very favorable safety profile. These data were published in The Lancet and independently described as a “major breakthrough” in the field by U.S. National Cancer Institute scientists. Inovio has achieved significant antigen-specific immune responses against multiple diseases and is advancing a growing pipeline of cancer and infectious disease immunotherapies and vaccines.

About Inovio Pharmaceuticals, Inc. 

Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that transform the treatment of cancer and infectious diseases. The ASPIRE (Antigen Specific Immune Responses) technology platform is designed to activate an individual’s immune system to generate a robust, targeted T cell and antibody response against targeted diseases. Inovio is the only immunotherapy company that has reported generating T cells entirely in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical precancer. Also in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Partners and collaborators include MedImmune, Regeneron, Roche/Genentech, ApolloBio Corporation, The Wistar Institute, University of Pennsylvania, the Parker Institute for Cancer Immunotherapy, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, National Institute of Allergy and Infectious Diseases, U.S. Army Medical Research Institute of Infectious Diseases, NIH, HIV Vaccines Trial Network, U.S. Military HIV Research Program and CEPI. For more information, visit www.inovio.com .

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, our plans and expectations regarding partnerships and the plans of GENEOS Therapeutics, Inc. to raise capital. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2017, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 and other regulatory filings we make from time to time. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

CONTACTS: Investors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 50

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 20

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 125

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 178

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 95

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 162

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 68

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 141

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 49

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading

Top 5 Most Recently Viewed Articles

BingX Enhances Trading Experience with CScalp Integration

Updated Category News Views 197

BingX Introduces Enhanced Trading Features with CScalp BingX, a prominent name in the cryptocurrency exchange sphere, has recently announced its integration with CScalp, a powerful trading terminal designed for both cryptocurrency and futures traders. This collaboration aims to provide users with cutting-edge trading tools, significantly enhancing their overall trading...

Continue Reading
Moscow Stocks Decline: Insights into Market Performance

Updated Category News Views 106

Moscow Stocks Face a Decline In the latest trading sessions, Moscow stocks have shown a clear downturn, with certain sectors especially driving this trend. The shifting dynamics within these sectors have created a challenging environment for investors. Performance by Sector and Important Takeaways The Telecoms, Mining, and Power sectors have been particularly tough,...

Continue Reading
Innovative Collaboration between Precision for Medicine and PathAI

Updated Category News Views 389

Strategic Alliance for Advancing Clinical Trials In a groundbreaking announcement, Precision for Medicine and PathAI are collaborating to revolutionize clinical trials and biomarker discovery. This partnership is set to introduce the next generation of AI-powered pathology tools designed to enhance quality control in clinical research. Enhancing Clinical Research...

Continue Reading
Declining Brazil Orange Juice Exports: Key Insights & Trends

Updated Category News Views 279

Overview of Brazil's Orange Juice Export Decline Brazil's orange juice exports have faced a significant downturn, with a 19.7% decrease in the first half of the 2024/25 crop season compared to the same time last year, as reported by CitrusBR. This decline represents approximately 535,600 metric tons of juice exports during this period, according to industry data....

Continue Reading
Celebrating 25 Years of Innovation in Legal Marketing

Updated Category News Views 164

Celebrating Two and a Half Decades of Digital Marketing PaperStreet Web Design, a pioneer in legal marketing, proudly marks its 25th anniversary. Founded by attorney and visionary Peter Boyd in 2001, this agency began as a one-person endeavor and has evolved into a nationally recognized firm employing over 30 professionals. With a rich history of aiding more than 2,500...

Continue Reading